M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery
NASHVILLE, TENNESSEE – M-LIFE™ announced the successful advancement of its anti-cancer prospect MLS-222QLD in preclinical testing. This molecule is one of several M-Life’s™ new generation of molecules aimed at the treatment of the most aggressive and untreatable forms of cancer. MLS-222QLD is a member of a new class of multi-targeting agent (MTA) cancer therapeutics that act upon both the cancer cellular mitosis and apoptosis pathways.
